Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Return on Assets (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Return on Assets for 5 consecutive years, with 0.47% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Assets fell 23.0% to 0.47% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.47%, a 23.0% decrease, with the full-year FY2024 number at 0.36%, down 2.0% from a year prior.
  • Return on Assets was 0.47% for Q3 2025 at 4D Molecular Therapeutics, down from 0.4% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.18% in Q2 2024 to a low of 0.47% in Q3 2025.
  • A 5-year average of 0.3% and a median of 0.28% in 2024 define the central range for Return on Assets.
  • Peak YoY movement for Return on Assets: increased 22bps in 2024, then fell -23bps in 2025.
  • 4D Molecular Therapeutics' Return on Assets stood at 0.24% in 2021, then tumbled by -65bps to 0.4% in 2022, then grew by 28bps to 0.29% in 2023, then increased by 4bps to 0.28% in 2024, then plummeted by -69bps to 0.47% in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Return on Assets are 0.47% (Q3 2025), 0.4% (Q2 2025), and 0.33% (Q1 2025).